Background
==========

In Croatia, lung cancer is the most frequently diagnosed cancer and the leading cause of cancer death in men. In women, it is the third most frequently diagnosed cancer and the second cause of cancer death, with poor overall survival \[[@b1-medscimonit-23-489]\]. Adenocarcinoma is the most common type of lung carcinoma, usually presenting in the advanced stage as an inoperable disease \[[@b2-medscimonit-23-489]\]. Therefore, minimally invasive procedures have to be employed in order to obtain tumor tissue for histological and molecular analysis \[[@b3-medscimonit-23-489]\]. The combination of TTF-1 and napsin A immunohistochemistry shows highly improved sensitivity and specificity for lung adenocarcinoma diagnosis \[[@b4-medscimonit-23-489],[@b5-medscimonit-23-489]\]. TTF-1 is a nuclear tissue-specific DNA-binding protein mainly expressed in thyroid follicular cells, type II pneumocytes, and nonciliated bronchiolar epithelial cells \[[@b6-medscimonit-23-489]\]. Napsin A is an aspartic proteinase involved in the maturation of the surfactant B \[[@b7-medscimonit-23-489]\]. Platinum-based chemotherapy is still the first-line therapy for advanced non-small cell lung cancer (NSCLC) \[[@b8-medscimonit-23-489]\], but in some patients chemotherapy does not have any clinical benefit \[[@b9-medscimonit-23-489]\]. ERCC1 is a nuclear protein involved in the nucleotide excision repair pathway essential for the repair of platinum-DNA adducts. ERCC1 is associated with resistance to platinum-based chemotherapy \[[@b10-medscimonit-23-489]\], so could be a prognostic and predictive biomarker \[[@b11-medscimonit-23-489],[@b12-medscimonit-23-489]\]. *EGFR* and *ALK* molecular testing is recommended to select patients with lung adenocarcinoma for targeted therapy with thyrosine kinase inhibitors (TKIs) \[[@b13-medscimonit-23-489]\]. *EGFR* mutation has been associated with lung adenocarcinoma, female sex, non-smokers, and Asian ethnicity, ranging from 24% to 66% \[[@b14-medscimonit-23-489]\]. Studies from the USA and Europe reported lower mutation rates, ranging from 13% to 17% \[[@b15-medscimonit-23-489],[@b16-medscimonit-23-489]\]. *ALK* rearrangement is another important finding in lung adenocarcinoma, ranging from 3% to 13% across different ethnicities, in young adult patients who never smoked \[[@b17-medscimonit-23-489]\]. Unfortunately, according to guidelines of Croatian health insurance, TKIs are not yet the first line of treatment for the patients with *EGFR* or *ALK* mutation, whose treatment still rests on platinum-based therapy. The present study was carried out in order to evaluate our institutional experience in daily practice and to provide an evidence-based approach for the utilization of immunohistochemical biomarkers and molecular testing in lung adenocarcinoma on small specimens, according to the recommendations for tissue management and guidelines for molecular testing \[[@b13-medscimonit-23-489]\].

Material and Methods
====================

Patients and tissue procurement
-------------------------------

From January 2013 till December 2014, 196 cases of new primary lung adenocarcinomas, 133 (68%) in males and 63 (32%) in females, were diagnosed at the Institute of Pathology, Forensic Medicine and Cytology, Clinical Hospital Center Split, Croatia. Among them, 142 (72%) were diagnosed on small biopsy, 36 (18%) on the surgical resection, 10 (5%) on transthoracic needle biopsies, and 8 (4%) on cytology samples. A total of 142 patients diagnosed only on small biopsy who did not undergo previous therapy were investigated in this study. None of the patients received neoadjuvant therapy. Original slides and paraffin blocks were collected from the archive, clinical data were collected from the hospital records of the Department of Pulmonology, and the time of death from the Mortality Registry. TNM staging of the disease was performed by imaging radiologic techniques. Overall survival was evaluated from the date of diagnosis until the end of March 2015 or the time of death, and patients treated with symptomatic therapy were excluded. Diagnosis of lung adenocarcinoma was performed based on morphology and immunohistochemical markers if necessary: cytokeratin (CK) 7, TTF-1, and napsin A. CK7 was obligatorily positive. Adenocarcinomas were subclassified into histological subtypes according to the latest World Health Organization (WHO) classification of lung carcinoma from 2015 \[[@b18-medscimonit-23-489]\]. Approval for the study was obtained from the Hospital Ethics Committee (code 500-03/15/01/42).

Immunohistochemistry
--------------------

The slides of tumor tissue were stained with monoclonal mouse antibodies napsin A (1:200), TTF-1 (1:100), and ERCC1 (4F9, ready to use) (all reagents DAKO, Glostrup, Denmark), and rabbit monoclonal antibody ALK (D5F3, Ventana, Tucson, Arizona). TTF-1, napsin A, and ERCC1 were visualized with the iVIEW DAB Detection Kit (Ventana, Tucson, Arizona) and ALK with the OptiView DAB ICH Detection Kit and the OptiView Amplification Kit (Ventana, Tucson, Arizona) on the automatic stainer BenchMark GX (Ventana, Tucson, Arizona). A total of 89 patients had a sufficient sample for immunohistochemical analysis for napsin A, 118 for TTF-1, 102 for ALK, and 73 for ERCC1. The results were analyzed by two pathologists on a light microscope Olympus 51 BX (Olympus, Tokyo, Japan). A positive expression of napsin A and ALK was shown as brown granular cytoplasmic staining and positive expression of TTF-1 as homogenous nuclear staining in any cell. ERCC1 staining was estimated on 100 tumor cells under light microscope at magnification of 400×. Percentages of positive tumor nuclei were determined, and staining intensity was graded on the scale 0 to 3. Respiratory epithelium with staining intensity of 2 was used as an internal positive control. By multiplying the staining intensity by the percentage of positive nuclei, the ERCC1 H score was determined, according to Besse et al. \[[@b12-medscimonit-23-489]\]. Median value of all H scores was used in order to classify tumors as ERCC1 positive or negative. Another way of discrimination was to use 0 to indicate ERCC1-negative tumors (no immunohistochemical reaction in any cell) and ERCC1 \>0 to indicate ERCC1-positive tumors (positive immunohistochemical reaction in any cell).

*EGFR* mutation detection by rtPCR
----------------------------------

A total of 113 patients had a sufficient sample for reflex molecular analysis of the *EGFR* mutation. Molecular analysis of the *EGFR* mutation was done at the time of diagnosis with a cobas EGFR Mutation Test (Roche, Basel, Switzerland) real-time polymerase chain reaction (rtPCR). A cobas Sample Preparation Kit (Roche, Basel, Switzerland) was used for sample preparation and DNA extraction. Automatic amplification and detection were done on a cobas z 480 Analyzer (Roche, Basel, Switzerland).

Statistical analysis
--------------------

Statistical significance was set at *p*\<0.05, and all confidence intervals (CIs) were at the 95% level. Statistical significance of the difference in categorical characteristics was calculated by using the χ^2^ test. Analysis of statistical significance of differences in numerical groups was performed with the Kruskal-Wallis test and of differences between two groups with the Mann-Whitney test. The Cox proportional model and logistic regression model were used to identify factors that might significantly influence survival. Survival curves were calculated according to the Kaplan-Meier method, and differences between curves were evaluated with the log-rank test. Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) software (version 19 for Windows; SPSS Inc., Chicago, Illinois, USA).

Results
=======

Clinicopathologic characteristics of lung adenocarcinoma patients and distribution of subtypes
----------------------------------------------------------------------------------------------

In 24 months, among 196 newly diagnosed patients with lung adenocarcinoma (ages 44--89 years), 133 (68%) were males and 63 (32%) were females. The cumulative incidence per 10,000 inhabitants was 9.5 (95% CI: 8.1--10.8); in females it was 5.6 (95% CI: 4.2--7) and in males it was 13.9 (95% CI: 11.5--16.2), which was 2.9 times more in males than in females. In our study, 142 patients with lung adenocarcinoma diagnosed only on small biopsy were analyzed: 95 (67%) males and 47 (33%) females. The median age was 64 years (minimum-maximum: 44--89 years). Within 27 months of follow-up, 76 (53.5%) patients died. Median survival was 8 months (SE: 0.87; 95% CI: 6.3--9.7). Solid subtype was found in 80 patients, acinar in 42, papillary in 15, and lepidic subtype in 5 patients. Patients were analyzed according to histologic subtype in relation to clinicopathologic characteristics ([Table 1](#t1-medscimonit-23-489){ref-type="table"}). No statistically significant difference was observed between solid and other subtypes in sex (χ^2^=0.061; *p*=0.805) and age (χ^2^=0.030; *p*=0.843). No statistically significant difference was observed between solid and other subtypes in TNM stage (χ^2^=5; *p*=0.171), tumor size (χ^2^=5.96; *p*=0.133), and lymph nodes (χ^2^=0.761; *p*=0.383). Nevertheless, when the stage I disease was excluded, the solid subtype was 2.4 times more common in the stage III disease with a level of significance of 92% (χ^2^=4.99; *p*=0.082). Metastases were observed 1.8 times more often in the acinar subtype compared with the solid subtype, with a level of significance of 94% (χ^2^=3.46; *p*=0.063). Napsin A expression correlated with TTF-1 positivity (χ^2^=28.25; *p*\<0.001). Among 18 napsin A-negative cases, 10 (55%) were TTF-1 negative, which was 13.7 times more than in napsin A-positive cases. Among 85 napsin A-positive cases, 64 (95%) were TTF-1 positive, which was 2 times more than in napsin A-negative cases. Among 68 TTF-1-positive cases, 41 (60%) had distant metastases, and among 16 TTF-1-negative cases, 14 had distant metastases (87%), which was 1.5 times more, with a level of significance of 92% (χ^2^=3.1; p=0.077). ERCC1 expression was negative in 23 (31%) patients. No statistically significant difference was found in ERCC1 expression between solid and other subtypes (z=0.148; *p*=0.882), as well as EGFR status (z=1.54; *p*=0.122). ALK expression was found in 4% of patients ([Figure 1A, 1B](#f1-medscimonit-23-489){ref-type="fig"}).

EGFR mutation status
--------------------

*EGFR* mutation was confirmed in 11 patients: 6 males and 5 females*.* Nine patients had exon 19 deletion (19 del), one had exon 21 L858R point mutation (L858R mutation), and one had a mutation on exon 18 G719X. They all had positive expression of TTF-1 and napsin A in tumor cells. The positive ALK expression and *EGFR* mutation were exclusive.

Survival analysis
-----------------

Overall survival ([Table 2](#t2-medscimonit-23-489){ref-type="table"}) was twice longer in TTF-1 and napsin A positive cases (*p*=0.007 and *p*=0.026, respectively). Overall survival was significantly associated with a lower TNM stage (*p*=0.001), negative lymph nodes (*p*=0.04), and negative distant metastasis (*p*\<0.001). The patients with stage II disease lived 1.6 times longer than the patients with stage III disease, and 2.8 times longer than the patients with stage IV disease. The patients treated with chemotherapy after surgical resection had an average survival 1.9 times longer than patients treated with chemotherapy alone, and 3.7 times longer than patients treated with the combination of chemotherapy and radiotherapy *(p*=0.001). No statistically significant difference in overall survival according to age (LR 0.13; *p*=0.722), sex (LR 1.5; *p*=0.218), smoking status (LR 0.59; *p*=0.439), tumor subtype (LR 0.483; *p*=0.487), tumor size (LR 3.8; *p*=0.285), and ERCC1 expression (LR 1.6; *p*=0.210) was found. Average survival of patients with *EGFR* mutation was 11 (9--13) months, and average survival of patients with wild type was 14 (7--12) months (LR 0.56; *p*=0.456). All variables were correlated with death ([Table 3](#t3-medscimonit-23-489){ref-type="table"}). The patients without expression of TTF-1 and napsin A had higher relative risk of death than those with a positive expression (*p*=0.011 and *p*=0.036, respectively) ([Figure 2A, 2B](#f2-medscimonit-23-489){ref-type="fig"}). The best discrimination between ERCC1-positive and ERCC1-negative tumors was obtained when any positive cell was used as the definition of an ERCC1-positive tumor (ERCC1\>0) and when no immunohistochemical reaction in any cell was used as the definition of an ERCC1-negative tumor (ERCC1=0). Using this definition, patients with ERCC1-positive tumors had 1.9 times higher relative risk for death (*p*=0.041) than patients with ERCC1-negative tumors ([Figure 3A, 3B](#f3-medscimonit-23-489){ref-type="fig"}). Relative risk of death rose by 1.2 times whenever ERCC1 expression rose (*p*=0.12), with a level of significance of 90%. Relative risk of death was strongly associated with distant metastasis (*p*=0.001) and lymph nodes (*p*=0.059), with a level of significance of 94%. All patients were treated with the chemotherapy based on platinum, alone or in combination with surgical resection or radiotherapy. The patients who received only chemotherapy were compared with others. The patients who were treated with chemotherapy and radiotherapy had a 2.4 times higher relative risk of death than the patients treated only by chemotherapy (*p*=0.009). The patients who received only chemotherapy had a 5.7 times higher risk of death than patients who underwent surgical resection and chemotherapy (*p*=0.087), with a level of significance of 91%.

Discussion
==========

Small biopsies are the most common tissue samples for the diagnosis of lung cancer, because 70% of patients present in advanced stages \[[@b13-medscimonit-23-489]\]. These data are largely in accordance with our observations: 72% adenocarcinomas were diagnosed on a small biopsy and 87.9% of patients presented in advanced stages. Solis et al. \[[@b19-medscimonit-23-489]\] found that solid subtype is a marker of unfavorable prognosis associated with advanced stages of disease compared with the acinar and lepidic subtypes. In our study, the solid and acinar subtypes were more common in advanced stage of disease. More common distant metastases in the acinar subtype could be explained by lung adenocarcinoma histologic heterogeneity, resulting in a discrepancy with the final histologic diagnosis in resection specimen \[[@b13-medscimonit-23-489]\]. The TTF-1 and napsin A expressions were positive in 81% and 78% cases, respectively, and were not associated with the tumor subtype. Zhang et al. showed the similar results for both markers, with positivity in 85% cases \[[@b20-medscimonit-23-489]\]. TTF-1 regulates the expression of napsin A, which explain their common coexpression \[[@b4-medscimonit-23-489]\]. The lower number of napsin A-positive cases in our study could be related to technical problems in sampling \[[@b21-medscimonit-23-489]\]. To the best of our knowledge, we have not found available data on the prognostic significance of TTF-1 and napsin A expression analyzed exclusively on small biopsy specimens, but only on resected specimens \[[@b22-medscimonit-23-489],[@b23-medscimonit-23-489]\]. Thus, the results reported herein extend the favorable prognosis related to a positive TTF-1 staining to the patients diagnosed only on a small biopsy specimen. The study highlights the decreased risk of distant metastases in TTF-1-positive patients. The overall survival was longer in TTF-1-positive and napsin A-positive patients. Ma et al. \[[@b23-medscimonit-23-489]\] showed that the expression levels of napsin A and TTF-1 are independent prognostic factors for survival. Zhan et al. concluded in meta-analysis that the overexpression of TTF-1 is associated with a favorable prognosis \[[@b22-medscimonit-23-489]\]. The reasons why TTF-1 is related to prognosis of patients with primary lung adenocarcinoma are unclear. Myong revealed that a positive TTF-1 staining has been inversely related to the proliferative activity evaluated through Ki-67 expression \[[@b24-medscimonit-23-489]\]. These observations suggest that TTF-1 and napsin A are not only useful diagnostic markers but also valuable prognostic markers in patients with lung adenocarcinoma and may play a role in molecular cancerogenesis. Overall survival was longer in patients without lymph node and distant metastasis and with a lower stage of disease, which is consistent with published data \[[@b2-medscimonit-23-489],[@b14-medscimonit-23-489],[@b16-medscimonit-23-489],[@b17-medscimonit-23-489]\]. Patients who underwent surgical resection and chemotherapy had a lower relative risk of death. A possible explanation for this could be that surgical therapy was performed in patients with lower stages of disease. All of our patients were treated with platinum-based chemotherapy, which targets DNA and induces damage that cancer cells struggle to overcome. ERCC1 expression levels have been explored as a marker of DNA repair capacity in tumor cells \[[@b9-medscimonit-23-489]--[@b11-medscimonit-23-489]\]. In our study, high ERCC1 expression was associated with increased relative risk for death and decreased overall survival. This effect may be attributed to increased DNA repair of platinum-induced DNA adducts in ERCC1-positive patients. Although low ERCC1 expression is generally associated with sensitivity to platinum, the published results are not always consistent. Several studies demonstrate that NSCLC patients treated with platinum-based therapy and having ERCC1-negative tumors had an increased survival \[[@b9-medscimonit-23-489]--[@b12-medscimonit-23-489],[@b25-medscimonit-23-489]\], but Booton et al. did not favor a prognostically better outcome \[[@b26-medscimonit-23-489]\]. Previous studies \[[@b8-medscimonit-23-489],[@b27-medscimonit-23-489]\] observed that *EGFR* mutation was associated with lower level of ERCC1 expression, which was not confirmed in our study, probably because the number of patients with *EGFR* mutation was too low. It can be postulated that decreased ability to repair DNA damage may be correlated with increased genome instability and tumor mutations. We did not find a correlation between lung adenocarcinoma subtype and *EGFR* status. Chen et al. showed an association between lepidic, papillary, and acinar subtypes and higher *EGFR* mutation rate, while the solid and mucinous components were associated with lower *EGFR* mutation rate \[[@b28-medscimonit-23-489]\]. Prognostic value of *EGFR* mutation in patients who did not receive TKIs was rarely reported \[[@b29-medscimonit-23-489]\]. In our study average survival of our patients according to *EGFR* status was not significantly different. *EGFR* mutation and ALK expression were mutually exclusive, as in the published literature \[[@b30-medscimonit-23-489]\].

Conclusions
===========

Following guidelines for good practice of small biopsy samples in patients with lung adenocarcinoma, we established a tissue management strategy to ensure the optimal treatment of patients who can benefit from new targeted therapies. Our data confirmed that TTF-1 and napsin A are not only useful diagnostic markers but also valuable prognostic markers in patients with lung adenocarcinoma. Positive ERCC1 expression was identified as a negative prognostic marker in patients treated with platinum-based therapy. The percentages of EGFR and ALK mutations corresponded to those in previously published reports for Caucasian patients.
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![ALK immunohistochemistry in lung adenocarcinoma: (**A**) negative expression and (**B**) strong and diffuse positive cytoplasmic expression in *ALK* rearranged lung adenocarcinoma (ALK/HRP 200×).](medscimonit-23-489-g001){#f1-medscimonit-23-489}

![Analysis of lung adenocarcinoma patients survival according to TTF-1 and napsin A expression using the Kaplan-Meier method. Positive expression of TTF-1 and napsin A expression were associated with longer overall survival in patients with lung adenocarcinoma. (**A**) TTF-1 and (**B**) napsin A.](medscimonit-23-489-g002){#f2-medscimonit-23-489}

![ERCC1 expression is associated with overall survival in patients with lung adenocarcinoma. (**A**) Positive and negative expression of ERCC1 in two cases of lung adenocarcinoma with respiratory epithelium as internal positive control (ERCC1/HRP 100×). (**B**) Among patients who were treated with platinum-based chemotherapy, the patients with negative expression of ERCC1 had longer overall survival.](medscimonit-23-489-g003){#f3-medscimonit-23-489}

###### 

N (%) of patients with lung adenocarcinoma according to histologic subtype in relation to clinicopathologic characteristics.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinicopathologic characteristics                          Patients\           Histologic subtype                                             
                                                             N (%)                                                                              
  ---------------------------------------------------------- ------------------- -------------------- ------------- ------------- ------------- -------------
  Age (years)                                                64 (44--89)         62 (50--75)          63 (44--82)   72 (59--89)   63 (47--88)   

  Sex                                                        Male                95 (100)             2             24 (25)       10            59 (62)

  Female                                                     47 (100)            3                    18 (38)       5             21 (45)       

  TNM stage                                                  1                   2 (100)              0             1             0             1

  2                                                          11 (100)            2                    2 (18)        2             5 (45)        

  3                                                          24 (100)            1                    5 (22)        0             18 (75)       

  4                                                          70 (100)            1                    26 (37)       8             35 (50)       

  Tumor[\*](#tfn2-medscimonit-23-489){ref-type="table-fn"}   T1                  11 (100)             1             3 (27)        3             4 (36)

  T2                                                         31 (100)            1                    10 (32)       3             17 (55)       

  T3                                                         26 (100)            1                    14 (54)       1             10 (38)       

  T4                                                         38 (100)            1                    68 (22)       4             25 (66)       

  Lymph nodes                                                Positive            92 (100)             3             29 (32)       6             54 (59)

  Metastasis                                                 Yes                 64 (100)             1             25 (39)       6             32 (50)

  Therapy                                                    CH                  71 (100)             1             26 (37)       4             40 (56)

  CH + SR                                                    11 (100)            2                    1 (9)         2             6 (56)        

  CH + RT                                                    15 (100)            1                    3 (20)        3             8 (53)        

  ST                                                         5 (100)             0                    1 (20)        0             4 (80)        

  TTF-1                                                      Negative            22 (100)             0             8 (36)        1             13 (59)

  Positive                                                   96 (100)            3                    27 (28))      9             57 (59)       

  Napsin A                                                   Negative            20 (100)             0             4 (20)        1             15 (75)

  Positive                                                   69 (100)            2                    20 (29)       7             40 (58)       

  ERCC1                                                      Median (min--max)   73                                 0.1 (0--3)    1 (1--3)      0.75 (0--3)

  EGFR                                                       Wild Type           102 (100)            4             32 (31)       10            56 (55)

  Mutated                                                    11 (100)            1                    3 (27)        2             5 (45)        

  ALK                                                        Negative            98 (100)             3             26 (26)       11            58 (59)

  Positive                                                   4 (100)             0                    2             1             1             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

CH -- chemotherapy; SR -- surgical resection; RT -- radiotherapy; ST -- symptomatic therapy.

WHO 2015 \[[@b18-medscimonit-23-489]\].

###### 

Mean and median of overall survival for patients with lung adenocarcinoma according to statistically significant variables.

  Variable                        Mean(SE); 95%CI       Median(SE); 95%CI   LR     *p*
  ---------- -------------------- --------------------- ------------------- ------ ---------
  TTF-1      Positive             13.3(1.2); 11--16     10(1); 8--12        7.3    0.007
  Negative   6.4(1,2); 4--8.9     5(2.3); 0.5--9.5                                 
  Napsin A   Positive             13.4(1.4); 10.8--16   9(1.2); 6.6--11     4.9    0.026
  Negative   6(0.96); 4--7.9      8(5); 0--18                                      
  N          No                   19(2.5); 14--24       8(0.75); 6.5--9.5   4.1    0.042
  Yes        10(1.1); 8--12                                                        
  M          No                   17.3(2); 13--21       19                  15.6   \<0.001
  Yes        8(1); 6--10          5(1); 3--7                                       
  TNM        2                    22.4(2,4); 17--27                         16     \<0.001
  3          13.7(2,4); 8.7--19   10(1.2); 7.7--12                                 
  4          8.1(1); 6--10        5(0.9); 3--7                                     
  Therapy    CH                   11.3(1.2); 9--14      8(0.8); 6--9.6      13.5   0.001
  CH + SR    22.4(2.4); 17--27                                                     
  CH + RT    6(2.2); 1.7--10      2(0.5); 1.1--2.9                                 

CH -- chemotherapy; SR -- surgical resection,; RT -- radiotherapy.

###### 

Cox regression analysis for Oscensor in 76 patients who died of lung adencarcinoma.

  Variable                 RR           95% CI        *p*
  ------------- ---------- ------------ ------------- ---------
  Sex           Male       0.743        0.455--1.22   0.237
  Age (years)   ≤64        0.923        0.584--1.5    0.732
  Subtype       Solid      1.12         0.876--1.42   0.376
  TTF-1         Negative   2.0          1.2--3.5      0.011
  Napsin A      Negative   1.9          1.0--3.6      0.036
  EGFR          Mutated    0.717        0.287--1.8    0.475
  T                        1.24         0.938--1.64   0.131
  N             Yes        2.66         0.96--7.4     0.059
  M             Yes        3.5          1.75--6.9     \<0.001
  TNM           2                                     0.003
  3             3.9        0.495--32    0.194         
  4             10.6       1.5--77      0.019         
  Therapy       CH                                    0.005
  CH + SR       0.176      0.024--1.3   0.087         
  CH + RT       2.4        1.2--4.6     0.009         
  ERCC1         Positive   1.9          1.0--3.5      0.041
  Negative                                            

CH -- chemotherapy; SR -- surgical resection; RT -- radiotherapy.
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